Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.

De Buck SS, Jakab A, Boehm M, Bootle D, Juric D, Quadt C, Goggin TK.

Br J Clin Pharmacol. 2014 Sep;78(3):543-55. doi: 10.1111/bcp.12378.

2.

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J.

J Clin Oncol. 2012 Jan 20;30(3):282-90. doi: 10.1200/JCO.2011.36.1360. Epub 2011 Dec 12.

PMID:
22162589
3.

Towards a better prediction of peak concentration, volume of distribution and half-life after oral drug administration in man, using allometry.

Sinha VK, Vaarties K, De Buck SS, Fenu LA, Nijsen M, Gilissen RA, Sanderson W, Van Uytsel K, Hoeben E, Van Peer A, Mackie CE, Smit JW.

Clin Pharmacokinet. 2011 May;50(5):307-18. doi: 10.2165/11539250-000000000-00000.

PMID:
21456631
4.
5.

Cardio-vascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay.

Fenu LA, Teisman A, De Buck SS, Sinha VK, Gilissen RA, Nijsen MJ, Mackie CE, Sanderson WE.

J Comput Aided Mol Des. 2009 Dec;23(12):883-95. doi: 10.1007/s10822-009-9306-z. Epub 2009 Nov 5.

PMID:
19890608
6.

Predicting oral clearance in humans: how close can we get with allometry?

Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RA, Van Peer A, Lavrijsen K, Mackie CE.

Clin Pharmacokinet. 2008;47(1):35-45.

PMID:
18076217
7.

Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation.

De Buck SS, Mackie CE.

Expert Opin Drug Metab Toxicol. 2007 Dec;3(6):865-78. Review.

PMID:
18028030
8.

Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.

De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, Gilissen RA.

Drug Metab Dispos. 2007 Oct;35(10):1766-80. Epub 2007 Jul 9.

PMID:
17620347
9.
10.

Immunopropylactic approaches against chemical carcinogenesis.

De Buck SS, Muller CP.

Vaccine. 2005 Mar 18;23(17-18):2403-6. Review.

PMID:
15755636
11.

Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers.

De Buck SS, Augustijns P, Muller CP.

J Pharmacol Exp Ther. 2005 May;313(2):640-6. Epub 2005 Jan 21.

PMID:
15665140
12.

Modulation of the metabolism and adverse effects of benzo[a]pyrene by a specific antibody: a novel host factor in environmental carcinogenesis?

De Buck SS, Bouche FB, Brandenburger A, Muller CP.

Carcinogenesis. 2005 Apr;26(4):835-44. Epub 2005 Jan 6.

PMID:
15637092

Supplemental Content

Loading ...
Support Center